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Patients with malignant melanoma and distant metastases 
generally have an unfavorable prognosis, with a median sur-
vival of about 6 months. The mechanisms of hematogenous 
spread and implantation of melanoma cells are, however, 
poorly understood, because the standard diagnostic methods 
are not sensitive enough to detect oligocellular micrometas-
tases. 
Recently a method using reverse transcription and polym-
erase chain reaction to determine tyrosinase mRNA in pe-
ripheral blood, which indicates the presence of circulating 
melanoma cells, has been developed. We utilized this assay to 
exaITline blood samples of 56 patients with malignant mela-
noma in different stages of disease. In one of 10 patients in 
M alignant melanoma accounts for 1-3% of all ma-lignant tumors [1]. Once disseminated beyond the regional lymph nodes, malignant melanoma is largely incurable, with a median survival of 4-6 months [1-4]. However, little is known about 
the rnechanisms of hematogenous spread and implantation of 
cancer cells circulating in peripheral blood, because a direct assess-
ment of circulating and micrometastatic cells would be required . 
The jrl vitro amplification of specific DNA sequences by polymer-
ase chain reaction (PCR) has opened new perspectives for detection 
of malignant cells, demonstrating that this is a potential tool for 
detection of cells in blood and bone marrow samples [5 - 8]. It can, 
however, only be performed when cancer-specific abnormalities in 
DN A are characterized or when tumor-gene expression is regulated 
in a tissue-specific manner. 
For the detection of the malignant melanoma cell tyrosinase, a 
key enzyme in melanin biosynthesis has been proposed [8]. Its ge-
nomic organization and cDNA sequence are well known [9]. The 
tyrosinase gene is actively expressed only in melanocytes and mela-
noma cells [9]. Because melanocytes do not usually circulate, the 
detection of tyrosinase RNA should indicate the presence of mela-
noma cells. 
Here we report the results of the combined method of reverse 
transcription and PCR (RT /PCR) analysis of peripheral blood sam-
ples for detection of melanoma cells in patients with malignant 
melanoma in different stages of disease. 
MATERIALS AND METHODS 
Patients Fifty-six patients with malignant melanoma (six with amelano-
tic melanoma) were examined (Table I) . In this analysis, a three-stage system 
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stage I (localized disease) and in six of 17 patients with re-
gional lymph nodes metastases (stage II) tyrosinase mRNA 
was detected. Tyrosinase transcripts were found in all 29 
pa.tients with distant metastases (stage III). Interestingly, tyr-
osmase mRNA was also detected in six patients with meta-
static amelanotic malignant melanoma. In contrast, tyrosin-
ase mRNA was not detectable in any of39 healthy subjects or 
17 patients with other malignancies. 
These findings may be helpful to define a patient group 
at high risk for systemic spread of disease. Key words: ma-
lignant melanoma/hematogenous spread/micrometastases/ 
polymerase chain reaction.] Illvest DermatoI101:887-889, 
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was. used that categorizes patients into clinically localized disease (stage I), 
reglOna.llymph node metastases (stage II) , and distant metastases (stage III). 
Additional blood samples of39 healthy subjects and 17 patients with other 
malignancies (one with basa.l cell carcinoma and 16 patients with advanced 
cancer) were tested. All 16 patients with metastatic malignancies in the 
disease control group (six with renal cell carcinoma, four with breast cancer, 
three with small cell lung cancer, three with colorectal carcinoma) had 
visceral metastases, with at least two involved organ sites. 
Synthetic oligonucleotides Tyrosinase primers were devised from pub-
lished sequences. The specificity of the amplified products was established 
by restriction enzyme digestion [8J. 
The outer primers (HTYR 1 = TTGGCAGATTGTCTGTAGCC and 
HTYR 2 = AGGCA TTGTGCATGCTGCTT) amplify a PCR product of 
284 base pairs (bp) and the nested primers (HTYR 3 = GTCTTTATG-
CAATGGAACGC and HTYR 4 = GCTATCCCAGTAAGTGGACT), 
a fragment of 207 bp. 
Glyceraldehyde-3-phosphate dehydrogenase primers (GA 1 and GA 2) 
were devised from the published gene sequence [10]. GA 1 = GGTCG-
GAGTCAACGGATTTG (sense), GA 2 = ATGAGCCCCAGCCTTCT-
CCAT (antisense) . They produce a fragment of 320 bp. 
For identification of the PCR product we used an oligonucleotide probe 
denved from the internal part of the amplified fragment (CAGCTGATG-
TACAA TTT AGATGCCTGAGTT). 
Sensitivity Testing To determine assay sensitivity we used two strate-
gies. First we performed a tenfold serial dilution experiment of human 
melanoma-derived cell line SK-mel-28 cells [11] to prepare suspensions of 
106 - 1 melanoma cell/ml and mixed the obtained melanoma cells in de-
creasing numbers with 10 ml of heparinized peripheral blood from a healthy 
subject. 
To verify the detection sensitivi ty of one melanoma cell, single SK-mel-
28 cells were aspirated with a heat-drawn capi llary under an inverted micro-
scope and added to normal blood samples. Total RNA was extracted from 
the cell mixture. Both experiments were replicated seven times. 
RT /PCR Method Samples of 10 ml heparinized blood were centrifuged 
at 1000 X g for 10 min and the supernatant decanted. 
Total RNA was isolated from the cell line SK-mel-28 and blood samples 
by acid guanidillium thiocyanate/phenol-ch loroform extraction as de-
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Table I. Patient Characteristics 
Number of PCR Results' 
Patients (PCR + ) 
Stage I' 
Clark level III (Breslow's 0.8 - 1.4 mm)' 
Clark level IV (Breslow's 1.6-3.9 mm) 
Growth pattern 
SSMJ 
Nodular 
Stage II 
N umber of metastatic nodes 
2-4 
>4 
Stage III 
Metastatic sites 
Distant lymph nodes 
Visceral 
10 
4 
6 
3 
7 
17 
7 
10 
29b 
4 
25 
1/10 
1/61 
1/7 
6/17 
2/7 
4/10 
29/29 
• Stage I, localized disease; stage II. regional lymph node metastases; stage 1II, distant 
metastases. 
• Six of 29 patients had a histologically proven amelanotic melanoma. 
, peR. polymerase chain reaction. 
J SSM. superficial spreading melanoma. 
'The given Breslow's thickness is the actual thickness range of examined patients. 
fThe single stage I - positive patient had an ulcerated nodular melanoma with tumor 
thickness of 3.9 mm. 
scribed by Chomczynsky and Sacchi [12). For reverse transcription, 1l1g of 
total cellular RNA was added to 25 III of reverse transcription buffer con-
taining 0.411mol of random hexomeres, 1 rnmol/I dNTP (dATP, dCTP, 
dTTP, dGTP), 24 units of AMV reverse transcriptase (Boehringer Mann-
heim) and 40 units RNasin (Promega). After incubation at42 °C for 1 h,2111 
of the sample was suspended in 50 III PCR buffer containing 0.311g HTYR 
1 and HTYR 2 primer and 2 units Taq DNA polymerase (Promega). PCR 
was carried out using a Thermal cycler (Perkin-Elmer). For the first round of 
amplification, we performed a "hot start" PCR by heating the samples to 
95°C for 10 min. Taq DNA polymerase was added after cooling to 85°C 
and 30 cycles (denaturation at 94°C for 90 seconds, anealing at 60°C for 90 
sec; and extension at 72°C for 90 seconds) were carried out. For the second 
round of amplification with nested primers HTYR 3 and HTYR 4 (0.3I1g of 
each primer), Sill of a 1 : 100 dilution were amplified for a further 30 cycles. 
Eight microliters of reaction product was run on 2% agarose gel, stained 
with ethidium bromide. Blood RNA integrity was checked by reverse tran-
scription PCR with primers for human glyceralaldehyde-3-phosphate 
dehydrogenase (GA 1 and GA 2). The origin of amplified product was 
confirmed by a non-isotopic Southern blot hybridization with a digoxi-
genin-labeled oligonucleotide probe derived from the internal part of the 
amplified fragment. The hybridization and chemiluminescent detection was 
performed using a commercially available kit (Lumigen PPD; Boehringer 
Mannheim). 
To safeguard against an inadvertent contamination and false positive re-
sults two negative and positive concurrent controls were prepared in tandem 
with the samples in every RNA extraction and two additional negative and 
positive controls were included with each PCR sample ru? Special precau-
tions, such as an ultraviolet (UV) hood, a separate set of pipettes for sample 
preparation, and separate working areas for sample preparations (for the 
handling of PCR products and positive controls), were taken to avoid con-
taminations. 
RESULTS 
We first studied the specificity and sensitivity of the RT jPCR 
method in detecting tyrosinase RNA in peripheral blood. The spec-
ificity of the amplified PCR products was established by the size of 
the fragments, deduced from their electrophoretic mobility (284 bp 
after the first round of amplification and 207 bp after following 
reamplification with the nested primers) a?d from non-isotopic 
Southern blot hybridization with a digoxigenin-labeled oligonu-
cleotide probe derived from the internal part of the amplified frag-
ment. 
To determine the sensitivity of this RT jPCR assay, we per-
formed a tenfold serial dilution experiment. Decreasing numbers of 
cells of human melanoma-derived cell line SK-mel-28 were mixed 
with 10 ml of heparinized blood and total RNA was extracted from 
the cell mixture. To determine the level of detection more accu-
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Figure 1. Sensitivity testing. Serial dilution of SK-mel-28 cells was per-. 
formed to prepare a solution of 106- 1 melanoma cell/ml. The obtained cells 
were added in decreasing numbers to 10 ml of heparinized blood from a 
healthy subject and total RNA was extracted from the mixture. RT /PCR 
was performed on 111g of total cellular RNA of each suspension and on a 
control sample containing no melanoma cells (the numbers above fOli es 3 -1 a 
represent the number of added SK-mel-28 cells). Eight microliters of the 
PCR product were electrophoresed on a 2% agarose gel and visualized by 
ethidium bromide staining after the first rOllnd of amplification with outer 
primers HTYR 1 and HTYR 2 (AJ, following reamplification with nested 
primers HTYR 3 and HTYR 4 (30 cycles each) (B). M, molecular-weight 
standards DNA ladder with 100-bp intervals between bands; C, no eDNA 
control. 
rately, single SK-mel-28 cells were aspirated with a heat-drawn 
capillary under an inverted microscope and added to normal blood 
samples. After the first round of amplification, positive bands were 
present at reciprocal dilutions of 104 -105. After the second round of 
PCR with nested primers we were able to reliably detect even one 
SK-mel-28 cell in 5 ml heparinized normal blood (Fig 1). To verify 
the detection sensitivity of one tumor cell, we performed seven 
replicates of both experiments. The peR product was detected in 
seven of seven assays using one SK-mel-28 cell in 5 ml blood. 
We then examined blood samples from 56 patients with malig-
nant melanoma in different stages of disease. In one of 10 patients 
with localized (stage I) disease and in six of 17 patients with regional 
lymph node metastases (stage II) , circul ating cells were present (Fig 
2). Tyrosinase mRNA was detected in all 29 patients with wide-
spread disease (stage III). Interestingly , in all six patients with meta-
static amelanotic m elanomas in this group, tyrosinase mRNA was 
reliably detected (11 = 6) . In contrast, no tyrosinase mRNA was 
detected in any of the 39 control blood samples of healthy persons or 
in 17 patients with other malignancies. 
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Figure 2_ Detection of tyrosinase mRNA in blood samples from patients 
with malignant melanoma in different stages of disease. Eight microliters of 
the peR product were electrophoresed on a 2% agarose gel and visualized by 
ethidiurn bromide staining. M, molecular-weight standards DNA ladder 
with 100-bp intervals between bands; 0, no eDNA control; P, positive 
control (SK-mel-28 cells); 1-2. negative controls (two healthy subjects); A, 
B patients in stage I; C,D patients in stage II; and E-H patients in stage III; 
G,H patients with histologically proved amelanotic malignant melanoma. 
DISCUSSION 
The possibility of analyzing blood specimens for the detection of 
circulating neoplastic cells has been explored during the last thr~e 
decades W'ith the hope of establishing a noninvasive tumor ~urveJl­
lance test to guide the clinician. However, current diagnostic te.ch-
niques are not sensitive enough despite the establishment of lIn-
munocytologic methods [13-15]. . ' 
We used reverse transcription and polymerase cham rea~tlon 
assays to detect melanoma cells in peripheral blood from patlen~s 
with lTI.alignant melanoma in different stages of the disease. ThiS 
method offers an extremely high sensitivity and we were even able 
ro reliabl y detect one melanoma cell in 5 Illl blood. We have not yet 
had any false positive results in other subjects. In none of 39 he~lthy 
persons or in 17 patients with other malignancies were tyrosm:lse 
rnRN A transcripts detected. . ' 
In contrast, circulating melanoma cells were found mall patlents 
with disseminated metastatic disease. Of special interest in our study 
is the finding that in six of 17 patients with regional lymph node 
metastases (stage II) and in only one of 10 patients With stage I 
disease W'ere melanoma cells detected in peripheral blood. 
CIRCULATING MELANOMA CELLS 889 
The prognostic relevance of systemic dissemination of sing le 
tumor cells has been demonstrated for gastrointestinal and breast 
cancer [16]. Therefore an important aspect of our findings is the 
possible prognostic and therapeutic significance of circulating mel-
anoma cells. This approach may be helpful to define a group of 
patients at high risk for development of hematogenous metastases, 
in whom adjuvant treatment strategies might be explored. 
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